摘要
目的：评价4种药物治疗急性脑梗死的成本-效果。方法对207例急性脑梗死患者资料进行回顾性分析，根据患者就诊时制定的药物治疗方案共分为4组：A组（前列地尔组51例）、B组（奥扎格雷组49例）、C组（丹红注射液组56例）、D组（血塞通组52例），分别观察其疗效和不良反应，并运用药物经济学成本-效果法进行分析。结果 A、B、C、D组成本分别为5248．6、4253．7、4475．8、3501．2元，有效率分别为92．2％、83．7％、87．5％、76．9％，成本-效果比（C/E）分别为56．93、50．82、51．15、45．53；A、B、C组相对于D组的增量成本-效果比（△C/△E）分别为107．2、110．7、91．9；不良反应发生率分别是3．9％、6．1％、12．5％、11.5％。结论前列地尔组方案为较佳治疗方案。
Objective To evaluate the treatment of acute cerebral infarction of 4 kinds of drug cost-effective-ness.Methods A retrospective analysis was performed on 207 patients with acute cerebral infarction,according to the drug formulation of patients treatment,they were divided into four groups： group A （alprostadil）,group B（Oza-grel）,group C（Dan red injection）,group D（Xuesaitong）,the curative effects and adverse reactions were observed and analyzed by using pharmacoeconomic cost-effectiveness method.Results The costs of groups A,B,C and D were 5 248.6,4 253.7,4 475.8,3 501.2 yuan,respectively;The effective rates were 92.2%,83.7%,87.5%,76.9%, respectively;The cost effectiveness ratio（C/E） were 56.93,50.82,51.15,45.53,respectively;A,B,C group compared with the incremental cost-D group,the effect of ratio（△C/△E） were 107.2,110.7,91.9;The incidence of adverse reactions were 3.9%,6.1%,12.5%,11.5%.Conclusion Alprostadil group scheme was the best treatment scheme.
出处
《中国基层医药》
CAS
2014年第21期3209-3211,共3页
Chinese Journal of Primary Medicine and Pharmacy
基金
天津市应用基础及前沿技术研究计划（12JCZDJC24100）
关键词
脑梗塞
药物疗法
成本及成本分析
Brain Infarction Drug Therapy Costs and Cost Analysis
